MK-1942 / Merck (MSD) 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-1942 / Merck (MSD)
MK-1942-008, NCT05602727 / 2021-006336-94: Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia

Terminated
2a/2b
99
Europe, Canada, Japan, US, RoW
MK-1942, Placebo
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Alzheimer's Disease
09/23
09/23
MK-1942-006, NCT04663321: Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD)

Terminated
2a
99
US
MK-1942, Placebo
Merck Sharp & Dohme LLC
Treatment Resistant Depression
09/23
09/23
2021-006336-94: Efficacy and Safety Trial of MK-1942 in Participants with Alzheimer’s Disease dementia (MK-1942-008) Eficacia y seguridad del estudio MK-1942 en participantes con demencia por enfermedad de Alzheimer (MK-1942-008).

Ongoing
2
408
Europe
MK-1942, MK-1942, Capsule, hard
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Alzheimer’s Disease dementia Demencia por enfermedad de Alzheimer, Mild to moderate Alzheimer’s disease dementia Demencia por enfermedad de Alzheimer de leve a moderada, Diseases [C] - Nervous System Diseases [C10]
 
 

Download Options